1 Introduction
Apatinib, a novel tyrosine kinase inhibitor targeted vascular
endothelial growth factor receptor-2 (VEGFR2) for solid tumors, has
revealed promising efficacy in treating liver cancer in China. Although
it has been reported to have a high incidence of inducing hand-foot skin
reactions, other skin adverse reactions induced by apatinib are rare.
Herein, we report a rare case of apatinib-induced severe bullous
dermatosis that was successfully treated with methylprednisolone and
summarize the dermatologic toxicities
of VEGFR tyrosine kinase inhibitor.
Key words: tyrosine kinase inhibitor, apatinib, drug adverse
reaction, bullous dermatosis